ß-thalassemia Major Clinical Trial
Official title:
An Open Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Efficacy of Deferasirox Administered to Chinese Patients With β-thalassemia Major Aged From 2 to Less Than 6 Years Old
To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00390858 -
A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload.
|
Phase 2 | |
Active, not recruiting |
NCT01846923 -
B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals
|
Phase 4 | |
Terminated |
NCT04205435 -
β-globin Restored Autologous HSC in β-thalassemia Major Patients
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT04592458 -
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
|
Phase 1 | |
Completed |
NCT01745120 -
A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants
|
Phase 1/Phase 2 | |
Recruiting |
NCT05776173 -
Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia
|
N/A |